Results 141 to 150 of about 28,689 (318)

Review of Treatment Options for Myelofibrosis: Focus on Ruxolitinib [PDF]

, 2013
Donal P. McLornan, John A. Laurie, Claire Harrison   +2 more
openalex   +1 more source

Efficacy of Momelotinib in Myelofibrosis Patients: Results From a Multicenter Study

European Journal of Haematology, EarlyView.
ABSTRACT Momelotinib, a novel JAK1/2 inhibitor with inhibitory activities on activin A receptor type I, has shown breakthrough clinical efficacy in patients with myelofibrosis (MF) and anemia, a disease‐related manifestation of challenging management. In this retrospective real‐life multicenter Italian study, we investigated the safety and efficacy of ...
Maria Carmen Martorelli, Novella Pugliese, Maria Di Perna, Danilo De Novellis, Assunta Lombardi, Laura De Fazio, Giuseppina Loglisci, Ilaria Peluso, Matteo Molica, Carolina Copia, Alessandra Ricco, Antonella Bruzzese, Francesco Mendicino, Vincenza De Fazio, Teresa Maria Santeramo, Rosario Bianco, Giuseppe Monaco, Raffaele Fontana, Roberto Guariglia, Bianca Serio, Serena Luponio, Anna Maria Della Corte, Antonella Malandrini, Valentina Giudice, Ferdinando Frigeri, Giuseppe Tarantini, Attilio Guarini, Massimo Gentile, Pellegrino Musto, Mario Annunziata, Nicola Di Renzo, Marco Rossi, Catello Califano, Fabrizio Pane, Carmine Selleri   +34 more
wiley   +1 more source

Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis [PDF]

, 2015
Cecilia Arana Yi, Constantine S. Tam, Srđan Verstovšek   +2 more
openalex   +1 more source

Ruxolitinib Phosphate

American Journal of Health-System Pharmacy, 2021
openaire   +2 more sources

Herpes Zoster in Hematological Disorders: Pathogenesis, Risk Stratification, and Emerging Strategies for Prevention and Immunization

European Journal of Haematology, EarlyView.
ABSTRACT Background Herpes zoster (HZ), resulting from reactivation of latent varicella‐zoster virus (VZV), imposes a significant burden on immunocompromised patients, particularly those with hematological malignancies and recipients of hematopoietic stem cell transplants (HSCT).
Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Santino Caserta, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source

Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE

Frontiers in Immunology
BackgroundUmbilical cord blood (UCB)-derived CD4+CD25+CD127low regulatory T cells (Tregs) can decrease albuminuria and anti-dsDNA IgG in systemic lupus erythematosus (SLE).
Mi-Ae Lyu, Ximing Tang, Maria Gabriela Raso, Meixian Huang, Ke Zeng, Tara Sadeghi, Christopher R. Flowers, Simrit Parmar   +7 more
doaj   +1 more source

Ruxolitinib Prior to Allogeneic Stem Cell Transplant: The Experience at Mayo Clinic Arizona [PDF]

, 2015
Veena Fauble, Pierre Noël, Ruben A. Mesa, Roberta H. Adams, José F. Leis, Nandita Khera, Lisa Sproat, Jeanne Palmer, Jeffrey Betcher, James L. Slack   +9 more
openalex   +1 more source

Regulatory T Cell Dysregulation in Vitiligo: A Meta‐Analysis and Systematic Review of Immune Mechanisms and Therapeutic Perspectives

International Journal of Dermatology, EarlyView.
Schematic representation of the methodology, key findings and implications in the context of immune mechanisms and treatment perspectives for vitiligo from the meta‐analysis and systematic review. ABSTRACT Vitiligo is an autoimmune disorder marked by the progressive loss of skin melanocytes, increasingly linked to immune dysregulation as a key driver ...
Gabriela Lerner, Maria Nikolaou, Corinne Stoffel, Eloi Schmauch, Thomas Kündig, Thierry Passeron, Julien Seneschal, Nanja van Geel, Ulrike Held, Antonios G. A. Kolios   +9 more
wiley   +1 more source

JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib [PDF]

, 2015
Lisa Pieri, Alessandro Pancrazzi, Annalisa Pacilli, Claudia Rabuzzi, Giada Rotunno, Tiziana Fanelli, Paola Guglielmelli, Rajmonda Fjerza, Chiara Paoli, Srđan Verstovšek, Alessandro M. Vannucchi   +10 more
openalex   +1 more source

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis

eJHaem
Bone marrow fibrosis (BMF) is a pathological feature of myelofibrosis, with higher grades associated with poor prognosis. Limited data exist on the association between outcomes and BMF changes.
Stephen T. Oh, Srdan Verstovsek, Vikas Gupta, Uwe Platzbecker, Timothy Devos, Jean‐Jacques Kiladjian, Donal P. McLornan, Andrew Perkins, Maria Laura Fox, Mary Frances McMullin, Adam J. Mead, Miklos Egyed, Jiri Mayer, Tomasz Sacha, Jun Kawashima, Mei Huang, Bryan Strouse, Ruben Mesa   +17 more
doaj   +1 more source